Valerio Therapeutics

As of December 31, 2024, Valerio Therapeutics carries a market capitalization of 11.23M, placing it among publicly traded companies globally. Its enterprise value stands at 24.16M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Valerio Therapeutics's next confirmed earnings release is scheduled for March 3, 2027.

As of December 31, 2024, Valerio Therapeutics has 153.88M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Valerio Therapeutics maintains a current ratio of 0.25, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 22, 2026, Valerio Therapeutics's stock has gained approximately 549.18% over the past 52 weeks. The 50-day moving average sits at 0.61, while the 200-day moving average is 0.35.

As of December 31, 2024, Valerio Therapeutics holds 1.18M in cash and equivalents against 13.44M in total debt, resulting in a net debt position of 11.75M. Total book value stands at -8.93M, with working capital of -13.77M providing operational flexibility.

Valerio Therapeutics's most recent stock split took place on March 17, 2021 with a 761:766 split ratio.